Core Concepts
Low MenACWY vaccine coverage among persons with HIV leads to an increase in meningococcal disease cases.
Abstract
The content discusses the rise in meningococcal disease cases among individuals with HIV in the United States, particularly focusing on the year 2022. It highlights the importance of MenACWY vaccination for this population and the concerning low coverage rates. The report emphasizes the need for healthcare providers to ensure proper vaccination and vigilance for symptoms of meningococcal disease in persons with HIV.
- Meningococcal disease is a life-threatening illness caused by Neisseria meningitidis.
- Symptoms of meningitis and meningococcemia include fever, headache, stiff neck, chills, fatigue, vomiting, diarrhea, cold hands and feet, and severe aches or pain.
- MenACWY vaccination is recommended for adolescents and individuals at risk for meningococcal disease, including those with HIV.
- Only 16.3% of persons with HIV received ≥1 doses of MenACWY vaccine within 2 years after diagnosis.
- A significant increase in meningococcal disease cases among persons with HIV was reported in 2022.
- Data is based on preliminary information, and case counts may rise with final reporting.
- MenACWY vaccine coverage among persons with HIV is low, necessitating healthcare providers to ensure vaccination adherence.
- A large serogroup C outbreak primarily affected men who have sex with men, but a notable increase in cases among persons with HIV remained.
- A single strain of N. meningitidis serogroup Y caused nine cases among persons with HIV in 2022, predominantly in Black or African American individuals and MSM.
- Healthcare providers are advised to screen all persons with HIV for meningococcal disease symptoms and ensure proper vaccination.
Stats
In a study from January 2016 to March 2018, only 16.3% of persons with HIV received ≥1 doses of MenACWY vaccine within 2 years after their diagnosis.
29 meningococcal disease cases have been reported among persons with HIV in 2022, accounting for 9.8% of all cases.
Among the 29 cases in 2022, 22 had not received MenACWY vaccine, six had unknown vaccination history, and one had received the vaccine, but the number of doses was unknown.
Quotes
"MenACWY vaccine coverage among persons with HIV is low."
"Health care providers should ensure that all persons with HIV are up to date with MenACWY vaccination per ACIP recommendations."